Title:
MTX-COVAB, a human-derived antibody with potent neutralizing activity against SARS-CoV-2 infection in vitro and in a hamster model of COVID-19
Authors:
Christoph Esslinger, Simone Schmitt, Marcel Weber, Matthias Hillenbrand, Jemima Seidenberg, Andreas Zingg, Catherine Townsend, Barbara Eicher, Justina Rutkauskaite, Peggy Riese, Carlos Alberto Guzman & Karsten Fischer
Published:
bioRxiv, 2 December 2020
[This article is a preprint and not yet certified by peer review.]
Abstract:
Fast track microfluidic screening of the antibody repertoires of 12 convalescent COVID-19 donors comprising 2.8mio antibodies yielded MTX-COVAB, a human-derived monoclonal antibody with low picomolar neutralization IC50 of SARS-CoV-2. COVAB neutralization potency is on par with the Regeneron cocktail as demonstrated in a comparative neutralization assay. MTX-COVAB shows strong efficacy in vivo and binds to all currently identified clinically relevant variants of SARS-CoV-2. MTX-COVAB completes GMP manufacturing by the end of this year and will be tested in the clinic in March 2021.